Jesse, Morgan, and Toby are back together to discuss the improving environment for US cannabis stocks. This is the fifth consecutive week of gains and broad US cannabis benchmarks are up over 50% this year. The boys analyze and appreciate the recent run in cannabis stocks and discuss how the space has evolved since the HHS announcement. They review the top performers AYR and Trulieve and those that have lagged like TerrAscend and The Cannabist. The conversation evolves into how the set of catalysts may play out in 2024, and the risk of remaining Schedule I or being moved to Schedule II. The conversation concludes by debating whether the space is investable with the 280E tax burden. 

Ver todos los episodios